Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | May 2, 2024
Data Byte
Four PDUFA dates coming in May
BMS awaits decisions on two new indications for Breyanzi; therapies from Ascendis, Dynavax also up for approvals
BioCentury | May 10, 2023
Discovery & Translation
Integrated’s AI platform to discover senolytic compounds; plus Editas’ transgene knock-in method and more
BioCentury’s roundup of translational news
BioCentury | Feb 4, 2023
Market Access
Rare diseases, MNCs grow presence on China’s NRDL
Even with big price reductions, China’s national reimbursement list is a lure for drug developers around the globe
BioCentury | Jan 11, 2023
Finance
Facing Humira cliff, AbbVie sees return to ‘strong growth’ by 2025
CEO Gonzalez predicts immunology drugs Skyrizi and Rinvoq will surpass Humira’s peak sales in 2027, says deals could augment post-2030 picture
BioCentury | Aug 5, 2022
Discovery & Translation
Daley lab’s iPSC-derived T cell differentiation method; plus Harbour’s CTLA-4 antibody and more
BioCentury’s roundup of translational news
BioCentury | Apr 27, 2022
Deals
Pfizer invests $25M in Zentalis, will advise on development of WEE1 program
Pharma lends Zentalis clinical expertise on a high-priority program, to which the biotech retains full ownership
BioCentury | Feb 10, 2022
Discovery & Translation
Translational trendspotting: a Distillery dive into neurology
Highlights include a new approach to the amyloid hypothesis, white space strategies for stroke and gene therapies
BioCentury | Dec 3, 2021
Discovery & Translation
Mapping the plasma proteome to identify drug targets; plus GSK-Vir, Codiak and more
BioCentury’s roundup of translational news
BioCentury | Aug 23, 2021
Deals
Pfizer sees potential best-in-class CD47s in $2.3B Trillium takeout
In high-premium deal, Pfizer gains fusion proteins for blood cancers
Items per page:
1 - 10 of 228